Pharmafile Logo
Pharmafocus logo
Advanced Search

UCB Pharma

Showing 10 posts of 10 posts found.

UCB Pharma’s bimekizumab improves skin clearance over Humira in plaque psoriasis

November 3, 2020
Manufacturing and Production, Research and Development UCB Pharma, bimekizumab, pharma

In recent Phase 3 study data presented European Academy of Dermatology and Venereology Congress last weekend, UCB Pharma reported that …

News

UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis

October 17, 2019
Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis

UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …

News

New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis

April 30, 2019
Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis

New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …

News

NICE recommends UCB’s Cimzia in severe plaque psoriasis

April 18, 2019
Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis

NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …

News
fdaoutsideweb

FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients

April 10, 2019
Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma

The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …

News

UCB teams up with charity to beat treatment-resistant epilepsy in $2.5m partnership

February 11, 2019
Research and Development, Sales and Marketing Epilepsy Society, UCB Pharma, epilepsy, pharma

Belgian firm UCB Pharma has announced a new partnership with the charity Epilepsy Society which will see the pair invest …

News
bonecells

Amgen and UCB’s Evenity approved in Japan for osteoporosis

January 9, 2019
Research and Development, Sales and Marketing Amgen, Japan, UCB Pharma, osteoporosis, pharma

Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval …

News
ucb_logo_and_chief_executive

UCB targets regulatory filing for its osteoporosis drug in 2016

March 3, 2016
Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …

News
ucb_logo

New epilepsy drug launches in UK

February 29, 2016
Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …

News

AbbVie VP joins UCB Pharma

January 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Pascale Richetta, UCB, UCB Pharma

Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February …

Appointment

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023